| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $263.5M | +60.6% |
| Cost of Revenue | $173.2M | +39.7% |
| R&D Expense | $300.3M | +6.4% |
| SG&A Expense | $152.3M | -0.5% |
| Operating Income | -$403.4M | -2.0% |
| Pre-tax Income | -$393.0M | -4.8% |
| Income Tax | -$2.1M | +26.8% |
| Net Income | -$391.0M | -5.1% |
| EPS (Basic) | -$1.09 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $163.1M | +41.0% |
| Short-term Investments | $133.9M | -35.7% |
| Accounts Receivable | $82.4M | +18.9% |
| Inventory | $51.7M | +0.3% |
| Current Assets | $442.7M | -3.1% |
| Total Assets | $913.2M | +0.3% |
| Current Liabilities | $138.4M | +13.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$302.4M | +14.3% |
| Capital Expenditures | $33.8M | +205.7% |
| Investing Cash Flow | $47.5M | +149.3% |
| Financing Cash Flow | $300.8M | -23.0% |
| Free Cash Flow | -$336.2M | +7.6% |
| +14.8% |
| EPS (Diluted) | -$1.09 | +14.8% |
| Total Liabilities |
| $214.6M |
| +7.3% |
| Stockholders' Equity | $698.6M | -1.7% |